ACIU vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ACIU's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 1/9 indicates extreme weakness in operational and financial health, while the absence of an Altman Z-Score raises unquantified bankruptcy risk. Despite a strong analyst consensus of 'strong_buy' and a target price of $8.98, the company exhibits catastrophic profitability metrics—negative ROE (-74.63%), gross and net margins at 0%, and a staggering -1671.88% operating margin. Revenue has collapsed by 96.3% YoY, and the stock trades at an absurd Price/Sales of 69.38, far exceeding peer benchmarks. The 52-week range ($1.43–$4.00) and 5-year decline of 62.7% underscore long-term underperformance, despite recent short-term price gains.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ACIU vs MRK: Head-to-Head Comparison
This page compares AC Immune SA (ACIU) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.